The convenient oral therapy could have benefits over more traditional infused taxane chemotherapies, and a new drug application filing is planned for 2021.
Odonate Therapeutics, Inc. is edging closer to bringing its first cancer therapy to market. Tesetaxel, a next-generation chemotherapy, could have convenience and tolerability benefits over older taxane chemotherapies like paclitaxel and docetaxel.
The company announced on 24 August that a Phase III trial testing tesetaxel in patients with HER2-negative, HR-positive metastatic breast cancer met the progression-free survival primary endpoint
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.
InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.
The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.
